Vanda Pharmaceuticals Inc (STU:VM4)
€ 4.62 -0.16 (-3.35%) Market Cap: 272.66 Mil Enterprise Value: -78.12 Mil PE Ratio: 0 PB Ratio: 0.54 GF Score: 79/100

Q2 2024 Vanda Pharmaceuticals Inc Earnings Call Transcript

Jul 31, 2024 / 08:30PM GMT
Release Date Price: €5.35 (-0.93%)
Operator

Thank you for standing by. My name is Meg, and I will be your conference operator today. At this time, I would like to welcome everyone to the Q2 2024 Vanda Pharmaceuticals, Inc. Earnings Conference Call. (Operator Instructions)

Thank you. I would now like to turn the conference over to Mr. Kevin Moran, Vanda's Chief Financial Officer. You may begin.

Kevin Moran
Vanda Pharmaceuticals Inc - Senior Vice President, Chief Financial Officer and Treasurer

Thank you, Meg. Good afternoon, and thank you for joining us to discuss Vanda Pharmaceuticals Second Quarter 2024 performance. Our second quarter 2024 results were released this afternoon and are available on the SEC's EDGAR system and on our website, www.vandapharma.com.

In addition, we are providing live and archived versions of this conference call on our website. Joining me on today's call is Dr. Mihael Polymeropoulos, our President, Chief Executive Officer and Chairman of the Board; and Tim Williams, our General Counsel.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot